Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Palmer JC et al. - ECE-2 expression is up-regulated, perhaps to minimize A beta accumulation, but this may also be a mechanism through which endothelin-1 production is increased and cerebral blood flow is reduced in AD. The findings suggest that endothelin-1 receptor antagonists, already licensed for treating other diseases, could be of benefit in AD therapies.

Related Articles

Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09    Relevance Score: 70%

Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09    Relevance Score: 69%

High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09    Relevance Score: 69%

New Cause for Alzheimer Disease
ScienceDaily, 11/30/09    Relevance Score: 68%

Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09    Relevance Score: 68%